A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

• Status: Completed
• Trial end date: 2015-08-01

Summary

Primary Objective:

To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).

Secondary Objective:

To assess the following:

• safety profile;

• progression free survival (PFS);

• overall survival (OS);

• pharmacokinetics (PK);

• immunogenicity.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept; Irinotecan; Leucovorin; Levoleucovorin